Research Outputs for 2012

* The Names in bold are CBTBR staff

Books / Chapters in Books (Total: 2)

  • De Wit E, Moller M, Hoal EG. (2012) Genetic Perspectives of Tuberculosis in Southern Africa. In: Genomics and Health in the Developing World, D Kumar (Ed) Oxford University Press, New York
  • Warner DF, Mizrahi V. (2012) Tuberculosis Drug Discovery: Target Identification and Validation. In: Drug Discovery in Africa (Chibale, K.C., Davies-Coleman, M. & Masimerembwa, C., eds.), Springer, ch. 3, pp. 53-84

Articles in Peer-Reviewed Journals (Total: 47)

  • Griffin JE, Pandey AK, Gilmore SA, Mizrahi V, McKinney JD, Bertozzi CR, Sassetti CM. (2012) Cholesterol catabolism by Mycobacterium tuberculosis requires transcriptional and metabolic adaptation. Chem Biol. 19(2): 218-227. (IF=5.976)
  • Warner DF, Mizrahi V. (2012) A pseudokinase debut at the mycobacterial cell wall. Sci Signal. 5(208):pe3. (IF=7.500)
  • Warner DF, Mizrahi V. (2012) Approaches to target identification and validation for tuberculosis drug discovery: a UCT perspective. S Afr Med J. 102(6): 457-460. (IF=1.610)
  • Abrahams GL, Kumar A, Savvi S, Hung AW, Wen S, Abell C, Barry CE III, Sherman DR, Boshoff HIM, Mizrahi V. (2012) Pathway-selective sensitization of Mycobacterium tuberculosis for target-based whole-cell screening, Chem Biol. 19:844-854. (IF=5.976)
  • Barnard M, Gey van Pittius NC, van Helden PD, Bosman M, Coetzee G, Warren RM. (2012) Diagnostic performance of Genotype® MTBDRplus Version 2 line probe assay is equivalent to the Xpert®MTB/RIF assay. J Clin. Microbiol. 50(11):3712-3716. (IF=4.258)
  • Chegou NN, Black GF, Loxton AG, Stanley K, Essone PN, Klein MR, Parida SK, Kaufmann SH, Doherty TM, Friggen AH, Franken KL, Ottenhoff TH, Wazlz G. (2012)  Potential of novel Mycobacterium tuberculosis infection phase-dependent antigens in the diagnosis of TB disease in a high burden setting. BMC Infect Dis. 12(1):10. (IF=3.011)
  • Chegou NN, Essone PN, Loxton AG, Stanley K, Black GF, van der Spuy GD, van Helden PD, Franken KL, Parida SK, Klein MR, Kaufmann SHE, Ottenhoff TH, Walzl G. (2012) Potential of Host Markers Produced by Infection Phase-dependent Antigen-stimulated Cells for the Diagnosis of Tuberculosis in a Highly Endemic Area. PLoS ONE. 7(6):e38501. (IF=4.610)
  • Chihota V, Müller B, Mlambo C, Pillay M, Tait M, Streicher EM, Marais E, Van der Spuy G, Hanekom M, Coetzee G, Trollip A, Hayes C, Bosman M, Gey van Pittius NC, Victor TC, Van Helden PD, Warren RM. (2012) The population structure of multi-and extensively drug-resistant tuberculosis in South Africa. J Clin Microbiol. 50(3): 995-1002. (IF=4.258)
  • Cohen T, van Helden PD, Wilson D, Colijn C, McLaughlin MM, Abubakar I, Warren RM. (2012) Mixed strain Mycobacterium tuberculosis infections: implications for tuberculosis treatment and control. Clin Microbiol Rev. 25(4):708-719. (IF=19.832)
  • De Beer JL, Kremer K, Ködmön C, Supply P, van Soolingen D,Global network for the molecular surveillance of tuberculosis 2009 (Consortium of authors include Warren RM (2012) First worldwide proficiency study on variable numbers of tandem repeats typing of Mycobacterium tuberculosis complex strains. J Clin Microbiol. 50(3): 662-669. (IF=4.258)
  • Diacon AH, Maritz S, Venter A, Van Helden PD, Dawson R, Donald P. (2012) Time to liquid culture positivity as a substitute for colony counting on agar plates in early bactericidal activity studies of antituberculosis agents. Clin. Microbiol Infect 18(7): 711-717. (IF=4.034)
  • Diacon AH, Dawson R, du Bois J, Narunsky K, Venter A, Donald PR, van Niekerk C, Erondu N, Ginsberg AM, Becker P, Spigelman MK. (2012) Phase II Dose-Ranging Trial of the Early Bactericidal Activity of PA-824. Antimicrob Agents Chemother. 56(6):3027-3031. (IF=4.680)
  • Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, Bantubani N, Narasimooloo R, De Marez T, van Heeswijk R, Lounis N, Meyvisch P, Andries K, McNeeley DF. (2012) Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother. 56(6): 3271-3276. (IF=4.680)
  • Donald PR, Maritz JS, Diacon AH. (2012) Pyrazinamide pharmacokinetics and efficacy in adults and children. Tuberculosis (Edinb) 92(1): 1-8. (IF=3.149)
  • Drewe JA, O’Riain MJ, Beamish E, Currie H, Parsons S. (2012) Survey of infections transmissible between baboons and humans, Cape Town, South Africa. Emerg Infect Dis 18(2): 298-301. (IF=6.996)
  • Gey van Pittius NC, van Helden PD, Warren RM. (2012) Characterization of Mycobacterium orygis. Letter in Emerg Infect Dis. 18(10):1708-1709. (IF=6.689)
  • Hatherill M, Verver S, Mahomed H; Taskforce on Clinical Research Issues, Stop TB Partnership Working Group on TB Vaccines (Walzl, G). (2012) Consensus statement on diagnostic end points or infant tuberculosis vaccine trials. Clin Infect Dis. 54(4): 493-501. (IF=7.898)
  • Hesseling AC, Kim S, Madhi S, Nachman S, Schaaf HS, Violari A, Victor TC, McSherry G, Mithell C, Cotton MF. (2012) High prevalence of drug resistance amongst HIV-exposed and –infected children in a tuberculosis prevention trial. Int J Tuberc Lung Dis 16(2): 192-195. (IF=2.426)
  • Katale BZ, Mbugi EV, Kendal S, Fyumagwa RD, Kibiki GS, Godfrey-Faussett P, Keyyu JD, van Helden PD, Matee MI. (2012) Bovine tuberculosis at the human-livestock-wildlife interface: Is it a public health problem in Tanzania? A review. Onderstepoort Journal of Veterinary Research. 79(2):1-8. (IF=0.890)
  • Kiser JJ, Zhu R, D’argenio DZ, Cotton MF, Bobat R, McSherry GD, Madhi SA, Carey VJ, Seifart HI, Werely CJ, Fletcher CV. (2012) Isoniazid Pharmacokinetics, Pharmacodynamics, and dosing in South African infants. Ther Drug Monit. 34(4):446-451. (IF=2.605)
  • Loxton AG, Black GF, Stanley K, Walzl G. (2012) Heparin-Binding Hemagglutinin Induces IFN-γ+ IL-2+ IL-17+ Multifunctional CD4+ T Cells during Latent but Not Active Tuberculosis Disease. Clin Vaccine Immunol. 19(5): 746-751. (IF=2.567)
  • Macingwana L, Baker B, Ngwane A, Harper C, Cotton M, Hesseling A,  Diacon A, van Helden PD, Wiid I. (2012) Sulfamethoxazole enhances the antimycobacterial activity of Rifampicin. J Antimicrob Chemother. 67:2908-2911. (IF=4.480)
  • Mandalakas AM, Kirchner HL, Lombard C, Walzl G, Grewal HMS, Gie RP, Hesseling AC. (2012) Well-quantified tuberculosis exposure is a reliable surrogate measure of tuberculosis infection. Int J Tuberc Lung Dis. 16(8):1033–1039. (IF=2.426)
  • Mbugi EV, Katale BZ, Kendall S, Good L, Kibiki GS, Keyyu JD, Godfrey-Faussett P, van Helden PD, Matee MI. (2012) ‘Tuberculosis cross-species transmission in Tanzania: Towards a One-Health concept. Onderstepoort Journal of Veterinary Research. 79(2):1-6. (IF=0.890)
  • Mbugi EV, Kayunze KA, Katale BZ, Kendall S, Good L, Kibik GS, Keyyu JD, Godfrey-Fausett P, van Helden PD, Matee MI. (2012) ‘One Health’ infectious diseases surveillance in Tanzania: Are we all on board the same flight? Onderstepoort Journal of Veterinary Research. 79(2):1-7. (IF=0.890)
  • McEvoy CRE, Cloete R, Muller B, Schurch AC, van Helden PD, Gagneux S, Warren RM, Gey van Pittius NC. (2012) Comparative analysis of Mycobacterium tuberculosis PE and PPE genes reveals high sequence variation and apparent absence of selective constraints. Plos One 7(4): e30593. (IF=4.610)
  • Miller M, Joubert J, Mathebelu N, De Klerk- Lorist L, Lyashchenko KP, Bengis R, van Helden PD, Hofmeyer M. Olea–Popelka F, Greenwald R, Esfandiara J, Buss P. (2012) Detection of antibodies to tuberculosis antigens in free –ranging lions (Panthera Leo) infected with Mycobacterium bovis in Kruger National Park, South Africa. JZWM 43(2): 317-323. (IF=0.710)
  • Muller A, Möller M, Adams LA, Warren RM, Hoal EG, van Helden PD. (2012) Comparative analysis of putative TB-susceptibility gene, MC3R (Melanocortin-3-receptor), and pseudogene sequence in cattle (Bos taurus), African buffalo (Syncerus caffer), hyena (Crocuta crocuta), rhino (Ceratotherium simum) and other African bovids and ruminants. Cytogenet Gen Res. 136(2): 117-122. (IF=2.074)
  • Mukinda FK, Theron D, Van der Spuy GD, Jacobson KR, Roscher M, Streicher EM, Musekiwa A, Coetzee GJ, Victor TC, Marais BJ, Nachega JB, Warren RM, Schaaf HS. (2012) Rise in Rifampicin-monoresistant Tuberculosis in Western Cape, South Africa. Int J Tuberc Lung Dis 16(2): 196-202. (IF=2.426)
  • Parsons SDC, Menezes AM, Cooper D, Walzl G, Warren RM, van Helden PD. (2012) Development of a diagnostic gene expression assay for tuberculosis and its use under field conditions in African buffaloes (Syncerus caffer). Veterinary Immunology and Immunopathology. 148(3-4):337-342. (IF=2.221)
  • Parsons SDC, Warren RM, Ottenhoff THM, Gey van Pittius NC, Van Helden PD. (2012) Detection of Mycobacterium tuberculosis infection in dogs in a high-risk setting.  Res Vet Sci. 92(3): 414-419. (IF=1.544)
  • Riou C, Peixoto BP, Roberts L, Ronacher K, Walzl G, Manca C, Rustomjee R, Mthiyane T, Fallows D, Gray CM, Kaplan G. (2012) Effect of standard Tuberculosis treatment on Plasma Cytokine levels in patients with Active Pulmonary Tuberculosis. PLoS One. 7(5):e36886. (IF=4.610)
  • Robertson BD, Altmann D, Barry C, Bishai B, Cole S, Thomas Dick, Duncan K, Dye C, Ehrt S, Esmail H, Flynn J, Hafner R, Handley G, Hanekom W, van Helden PD, Kaplan G, Kaufmann SH, Kim P, Lienhardt C, Mizrahi V, Rubin E, Schnappinger D, Sherman D, Thole J, Vandal O, Walzl G, Warner D, Wilkinson R, Young D. (2012) Detection and treatment of subclinical tuberculosis. Tuberculosis (Edinb). 92 (6):447-452.(IF=3.149)
  • Seddon JA, Hesseling AC, Marais BJ, Jordaan AM, Victor TC, Schaaf HS. (2012) The evolving epidemic of drug-resistant tuberculosis among children in Cape Town, South Africa. Int J Tuberc Lung Dis. 16(7):928–933. (IF=2.426)
  • Seddon JA, Jordaan AM, Victor TC, Schaaf HS. (2012) Discordant Drug Susceptibility for Mycobacterium tuberculosis within Families. Pediatr Infect Dis J. 31(7): 783-785. (IF=3.271)
  • Seddon JA, Visser DH, Bartens M, Jordaan AM, Victor TC, van Furth AM, Schoeman JF, Schaaf HS. (2012) Impact of drug resistance on clinical outcome in children with tuberculous meningitis. Pedriatr Infect Dis J 31(7): 711-716. (IF=3.271)
  • Seddon JA, Warren RM, Enarson DA, Beyers N, Schaaf HS. (2012) Drug-resistant tuberculosis in children is caused by transmission and amplification of resistance within families. Emerg Infect Dis 18(8):1342-1345 (IF=6.996)
  • Sirgel FA, Tait M, Warren RM, Streicher EM, Böttger EC, van Helden PD, Gey Van Pittius NC, Coetzee G, Hoosain EY, Chabula-Nxiweni M, Hayes C, Victor TC, Trollip A. (2012) Mutations in the rrs A1401G Gene and Phenotypic Resistance to Amikacin and Capreomycin in Mycobacterium tuberculosis. Microb Drug Resist. 18(2): 193-197. (IF=1.847)
  • Sirgel FA, Warren RM, Streicher EM, Victor TC, van Helden PD, Böttger EC. (2012) gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother. 67(5): 1088-1093. (IF=4.480)
  • Streicher EM, Bergval I, Dheda K, Bottger E, Gey van Pittius NC, Bosman M, Coetzee G, Anthony R, van Helden PD, Victor TC, Warren RM. (2012) Mycobacterium tuberculosis population structure determines the outcome of genetic based second-line drug testing. Antimicrob. Agents Chemother. 56(5): 2420-2427. (IF=4.680)
  • Streicher EM, Müller B, Chihota V, Mlambo C, Tait M, Pillay M, Trollip A, Hoek KGP, Sirgel FA, Gey van Pittius NC, Van Helden PD, Victor TC, Warren RM. (2012) Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa. Infection, Genetics and Evolution. 12(4):686–694. (IF=3.055)
  • Van Rie A, Mellet K, John M-A, Scott L, Page-Shipp L, Dansey H, Victor TC, Warren RM. (2012) False positive Rifampicin resistance on Xpert®MTB/RIF: case report and clinical implications. Int J Tuberc Lung Dis 16(2): 206-208. (IF=2.426)
  • Van Schalkwyk C, Cule M, Welte A, van Helden PD, van der Spuy G, Uys P. (2012) Towards eliminating bias in Cluster Analysis of TB Genotyped data. PloS One. 7(3):e34109 (IF=4.610)
  • Van Soelen N, Mandalakas AM, Kirchner HL, Walzl G, Grewal HM, Jacobsen M, Hesseling AC. (2012) Effect of Ascaris Lumbricoides specific IgE on tuberculin skin test responses in children in a high-burden setting: a cross-sectional community-based study. BMC Infect Dis. 12(1):211 (IF=3.236)
  • Visser ME, Stead MC, Walzl G, Warren RM, Schomaker M, Grewal HM, Swart EC, Maartens G. (2012) Baseline predictors of sputum culture conversion in pulmonary tuberculosis: importance of cavities, smoking, time to detection an w-beijing genotype. PloS One 7(1): e29588. (IF=4.610)
  • Weiner B, Gomez J, Victor TC, Warren RM, Sloutsky A, Plikatis BB, Posey JE, van Helden PD, Gey van Pittius NC, Koehrsen M, Sisk P, Stolte C, White J, Gagneux S, Birren B, Hung D, Murray M, Galagen J. (2012) Independent large scale duplications in multiple M. tuberculosis lineages overlapping the same genomic region. PloS One 7(2): e26038. (IF=4.610)
  • Zhu R, Kiser JJ, Seifart HI, Werely CJ, Mitchell CD, D’Argenio DZ, Fletcher CV. (2012) The Pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid. J Clin Pharmacol. 52(4): 511-519. (IF=3.387)

Non Peer-Reviewed Articles (Total: 3)

  • Van Helden PD. (2012) Simplicity. EMBO reports 13:172. (IF=7.488)
  • Van Helden PD. (2012) The cost of research in developing countries. EMBO reports 13(5): 395. (IF=7.488)
  • Van Helden PD. (2012) Not too much and not too little. EMBO Reports. 13:942.

Published Abstracts (Total: 0)

Technical Reports (Total: 0)

Products / Artefacts / Patents (Total: 0)

Conferences/Meetings Attended & Invited Talks/Seminars Presented (Total: 92)

Plenary/Keynote/ Distinguished Lectures

  • Mizrahi V. Development and Application of New Tools for TB Drug Discovery: A View from South Africa. Keynote lecture presented at the 4th Annual CEND Symposium: Fighting the Diseases of Poverty, Centre for Emerging and Neglected Diseases, UC Berkeley, 13 January 2012
  • Mizrahi V. New Tools for TB Drug Discovery. Plenary lecture delivered at the Symposium on Scientific Advances in TB Pathogenesis and Treatment, 10th Conference on Retroviruses and Opportunistic Infections (CROI 2012), Seattle, WA, 5-9 March 2012
  • Mizrahi V. Drug Resistance in TB: Scope of the problem and underlying mechanisms. Lecture presented at the pre-Symposium Workshop. Keystone Symposium on Drug Resistance and Persistence in Tuberculosis, Speke Resort, Kampala, Uganda, 13-18 May 2012
  • Mizrahi V. Mechanisms driving mutations to drug resistance. Plenary lecture presented at the Keystone Symposium on Drug Resistance and Persistence in Tuberculosis, Speke Resort, Kampala, Uganda, 13-18 May 2012
  • Mizrahi V. New Tools for TB Drug Discovery. Plenary lecture presented at the 3rd SA TB Conference 2012, Durban, 12-15 June 2012
  • Mizrahi V. Knowing the Enemy: Survival and Subversion Strategies of Mycobacterium tuberculosis. Inaugural Lecture, University of Cape Town, 22 August 2012.
  • Mizrahi V. New Tools for Tuberculosis Drug Discovery: A South African Perspective. Wolfson Colloquium, University of Cape Town, 4 September 2012.
  • Mizrahi V. Pathway-selective sensitization of Mycobacterium tuberculosis for use in target-based whole-cell screening. Invited lecture presented at the H3-D Symposium on New Paradigms in Drug Discovery: Challenges and Opportunities in Africa, 16 October 2012.
  • Kana B. Peptidoglycan remodelling during mycobacterial growth and persistence. Opening talk in the “Innovations from Africa Theme”. Kwazulu-Natal Research Institute for TB and HIV (K-RITH) Opening Scientific Symposium. Hilton Hotel, Durban, South Africa. 10th October 2012.

Invited Talks

  • Mizrahi V. New Tools for TB Drug Discovery. Invited lecture presented at the Department of Medicine Seminar Series, University of Cape Town, 15 March 2012
  • Evans J, Mizrahi V. Identifying vulnerable targets in the CoA biosynthetic pathway of M. tuberculosis. Lecture presented at the Kick-Off meeting, High-Quality Hits for Tuberculosis (HIT-TB) Consortium, Cambridge, UK, 27 March 2012
  • Mizrahi V. Mechanisms driving mutations to drug resistance. Lecture presented at the IIDMM/ICGEB Seminar Series, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, 9 May 2012
  • Singh V, Warner DF, Mizrahi V. Pyrimidine metabolism in M. tuberculosis – an update from UCT. Invited talk presented at the Fourth Consortium Meeting, More Medicines for Tuberculosis (MM4TB), Tällberg, Sweden, 5-6 July 2012
  • Gopinath K, McKinney JD, Mizrahi V, Warner DF. BacA is essential for vitamin B12 transport in M. tuberculosis. Invited talk presented at Tuberculosis 2012, Paris, 11-15 September, 2012
  • Gopinath K, McKinney JD, Mizrahi V, Warner DF. Identification of genes requires for transport and assimilation of vitamin B12 in M. tuberculosis. Invited talk presented at the Vitamin B12 Symposium, Nancy, France, 20-22 September 2012.
  • Mizrahi V. Pathway-selective sensitization of Mycobacterium tuberculosis for use in target-based whole-cell screening. Invited talk presented at the H3-D Symposium on New Paradigms in Drug Discovery, Cape Town, 16 October 2012.
  • Kana B. Remodelling the mycobacterial cell wall for new TB drugs. Invited talk at École polytechnique fédérale de Lausanne EPFL. Lausanne, Switzerland, 7th September 2012.
  • Kana B. Remodelling the mycobacterial cell wall for new TB drugs. Invited talk at the University of Leicester. Leicester, United Kingdom. 10th July 2012.
  • Kana B. Peptidoglycan remodelling during TB infection. Invited talk at the Kwazulu-Natal Research Institute for TB and HIV (K-RITH), Durban, South African, 31st May 2012.
  • Kana B. Career Guidance for young scientists and NRF ratings. Oral presentation at the Research Indaba. Midrand graduate institute. Johannesburg. 22nd October 2012.
  • Kana B. How to Build an Academic Career in Science. Oral presentation at the Research Capacity Building Session of the 3rd SA TB Conference. International Convention Centre, Durban, South Africa. 12-15 June 2012.
  • Kana B. Building an Academic Career in Science. Invited talk given at the Career Guidance for Young Scientists Workshop at theSASBMB/FASBMB Congress 2012 - The South African Society of Biochemistry and Molecular Biology. Champagne Sports Resort, Drakensberg, KwaZulu-Natal, 29 January – 1 February 2012.
  • Hassim F, Gordhan B. Construction and phenotypic characterization of M. smegmatis mutants deficient in the MutY DNA glycosylase. Oral presentation at the Wits Health Sciences Research Day & Postgraduate Expo 2012. Wits Medical School, Johannesburg, South Africa, 19th September 2012.
  • Hassim F, Gordhan B. Construction and phenotypic characterization of M. smegmatis mutants deficient in the MutY DNA glycosylase. Oral presentation at the MRC Early Career Scientists Conference 2012, 24th – 25th October 2012.
  • Narrandes N, Mizrahi V, Kana B. Functional characterization of molybdopterin synthase encoding genes in mycobacteria. Oral presentation at the SASBMB/FASBMB Congress 2012 - The South African Society of Biochemistry and Molecular Biology. Champagne Sports Resort, Drakensberg, KwaZulu-Natal, 29 January – 1 February 2012.
  • Narrandes N, Mizrahi V, Kana B. Functional characterization of molybdopterin synthase encoding genes in mycobacteria. Oral presentation at the Wits Health Sciences Research Day & Postgraduate Expo 2012. Wits Medical School, Johannesburg, South Africa, 19th September 2012.
  • Sensani S. My Journey at the CBTBR. Oral presentation at the DST/NRF Centre of Excellence Director’s Forum. Sanlam Centre, Pretoria, South Africa. 13th November 2012
  • Senzani S, Kana B. Analysis of peptidoglycan degrading amidases. Oral presentation at the MRC Early Career Scientists Conference 2012, 24th – 25th October 2012.
  • Moolla N, Gordhan B. Construction and Phenotypic Characterization of Mycobacterium smegmatis Mutants Deficient in the Nth DNA Glycosylase. Oral presentation at the MRC Early Career Scientists Conference 2012, 24th – 25th October 2012.
  • Ealand C, Kana B. The role of mycobacterial DD-carboxypeptidases in peptidoglycan remodeling and turnover. Oral presentation at the SASBMB/FASBMB Congress 2012 - The South African Society of Biochemistry and Molecular Biology. Champagne Sports Resort, Drakensberg, KwaZulu-Natal, 29 January – 1 February 2012.
  • Ealand C, Kana B. The role of mycobacterial DD-carboxypeptidases in peptidoglycan remodeling and turnover. Oral presentation at the Wits Health Sciences Research Day & Postgraduate Expo 2012. Wits Medical School, Johannesburg, South Africa, 19th September 2012.
  • Ealand C, Kana B. The role of mycobacterial DD-carboxypeptidases in peptidoglycan remodeling and turnover. Oral and poster presentation at the MRC Early Career Scientists Conference 2012, 24th – 25th October 2012.
  • Hoal EG. Genomics of Infectious Diseases in Africa. Invited talk presented at the Golden Helix Symposia: Genomic Medicine: Translating Genes into Health. 18-21 April 2012. Turin, Italy.
  • Warren RM. Characterizing Drug-Resistant TB epidemics in South Africa. Invited talk presented at Stellenbosch University. 19th April 2012.   
  • Le Roux N. Host genetic susceptibility to M. bovis in buffalo. Talk presented at the Annual Bovine TB Workshop, Kruger National Park, May 2012.
  • Grobbelaar M. Adaptation of the Mycobacterium tuberculosis transcriptome in response to Rifampicin. Talk presented at the Keystone Symposia, Uganda during 13-18 May 2012.
  • Parsons SDC. Adaptation of the QuantiFERON TB-Gold assay for the diagnosis of TB in wildlife. Talk presented at the International Wildlife TB Conference, Skukuza, Kruger national Park, South Africa, May 2012.
  • Parsons SDC. Development of a Gene Expression Assay for the diagnosis of TB. Talk presented at a meeting of the BTB Study Group, Skukuza, KNP, September 2012.
  • Warren RM. Deciphering the Epidemiology of drug-resistant tuberculosis through comparative genomics. Invited speaker at the 6th Annual New England TB Symposium, Focus on Drug-resistance, Broad Institute, Cambridge, 28 June 2012.
  • Le Roux N. Novel SNP identification and association with bovine TB in African buffalo. Invited talk presented at the International Society of Animal Genetics (ISAG) 2012 conference, Cairns, Australia, 15-20 July 2012.
  • Klopper M. Molecular characterization of the drug-resistant tuberculosis epidemic in the Eastern Cape, South Africa. Talk presented at SACEMA Research day, Stellenbosch, April 2012.
  • Streicher EM. Mycobacterium tuberculosis population structure determines the outcome of genetic based second-line drug resistance testing. Talk presented at the Keystone Symposium, Drug Resistance and Persistence in Tuberculosis, Kampala Uganda, May 2012.
  • Fortuin S. The evolution of the Mycobacterium tuberculosis proteome. Invited speaker at the Welcome Trust All Directors Meeting, Accra, Ghana 2012.
  • Fortuin S. Identification of virulence proteins of Mycobacterium tuberculosis. Invited speaker at the Southern Africa Consortium for Research Excellence Annual Meeting, Gaborone, Botswana, September 2012.
  • Fortuin S. The phosphoproteomes of a hypo- and hyper-virulent clinical M. tuberculosis Beijing strains. Talk presented at the Stellenbosch University 56th Annual Academic Year day 2012, 15-16 August 2012.
  • Van Helden PD. Molecular Epidemiology of Mycobacterium TB. Invited talk presented at the SA Clinicians Society Conference 2012, Cape Town, South Africa, 25-28 November 2012.
  • Van Helden PD. Antibiotics and omics of TB. Invited talk presented at the Structural Biology in the Bio Economy Conference, Cape Town, South Africa, 2-4 December 2012.
  • Walzl G. TB biomarkers in peripheral blood. Invited talk presented at the 43rd Union World Conference on Lung Health, Kuala Lumpur Malaysia , 13-17 November 2012.
  • Walzl G. Clinical impact of recent advances for the prevention, diagnosis and treatment of tuberculosis. Invited talk presented at the European Respiratory Society Annual Congress, 1-5 September 2012, Vienna, Austria.
  • Walzl G. Lessons from the search for biomarkers for active TB and TB treatment response.  Invited talk presented at the Joint EVI/TBVI Symposium. Les Diablerets, Switzerland, 31 January 2012.
  • Walzl G. Utility of multiplex cytokine arrays in TB biomarker discovery. Invited talk presented at the Tuberculosis Research Unit Annual meeting, Cleveland, USA, 26-27 November 2012.
  • Le Roux N. Novel SNP identification and association with bovine TB in African buffalo. Talk presented at the International Wildlife Tuberculosis Conference, Kruger National Park, South Africa, 9-12 September 2012.
  • Werely CJW. TB treatment considerations for neonates and infants. Talk presented at the 43rd Union World Conference on Lung Health, Kuala Lumpur, Malaysia, 13-17 November 2012.

Posters

  • Koch, A., Mizrahi, V., Warner, D.F. Physiology of drug-resistant mycobacteria: implications for pathogenesis. Poster presented at the Keystone Symposium on Drug Resistance and Persistence in Tuberculosis, Speke Resort, Kampala, Uganda, 13-18 May 2012.
  • Mapela L, Beukes G, Senzani S, Kana B. Peptidoglycan remodelling in mycobacterial growth and pathogenesis. Poster presentation at the Tuberculosis 2012: Biology, pathogenesis, intervention strategies. Institut Pasteur, Paris, France, 11th-15th September 2012.
  • Kana B. Resuscitation promoting factors in bacterial growth and cell wall remodelling - Extreme Makeover for the Cell wall.  Poster presentation at the Annual HHMI Scholars Meeting. HHMI Headquarters, Chevy Chase, Maryland, USA. 14-17 February 2012.
  • Asmal R, Kana B. Identification and cellular localization of DD-Carboxypeptidase-interacting proteins in Mycobacterium smegmatis. Poster presentation at the 4th Cross Faculty Graduate Symposium: Showcasing Postgraduate Research at Wits 2012. Wits University – Professional Development Hub, Johannesburg, South Africa. 19th and 22nd October.
  • Asmal R, Kana B. Identification and cellular localization of DD-Carboxypeptidase-interacting proteins in Mycobacterium smegmatis. Poster presentation at the Wits Health Sciences Research Day & Postgraduate Expo 2012. Wits Medical School, Johannesburg, South Africa, 19th September 2012.
  • Hassim F, Gordhan B. Construction and phenotypic characterization of M. smegmatis mutants deficient in the MutY DNA glycosylase. Poster presentation at the SASBMB/FASBMB Congress 2012 - The South African Society of Biochemistry and Molecular Biology. Champagne Sports Resort, Drakensberg, KwaZulu-Natal, 29 January – 1 February 2012.
  • Narrandes N, Mizrahi V, Kana B. Functional characterization of molybdopterin synthase encoding genes in mycobacteria. Poster presentation at the Tuberculosis 2012: Biology, pathogenesis, intervention strategies. Institut Pasteur, Paris, France, 11th-15th September 2012.
  • Narrandes N, Mizrahi V, Kana B. Functional characterization of molybdopterin synthase encoding genes in mycobacteria. Poster presentation at the 4th Cross Faculty Graduate Symposium: Showcasing Postgraduate Research at Wits 2012. Wits University – Professional Development Hub, Johannesburg, South Africa. 19th and 22nd October.
  • Senzani S, Kana B. Analysis of peptidoglycan degrading amidases. Poster presentation at the Wits Health Sciences Research Day & Postgraduate Expo 2012. Wits Medical School, Johannesburg, South Africa, 19th September 2012.
  • Senzani S, Kana B. The role of resuscitation promoting factors in peptidoglycan hydrolysis and reactivation from dormancy in Mycobacterium smegmatis. Poster presentation at the SASBMB/FASBMB Congress 2012. Champagne Sports Resort, Drakensberg, KwaZulu-Natal, 29 January – 1 February 2012.
  • Beukes G, Mapela L, Kana B. The role of resuscitation promoting factors in peptidoglycan hydrolysis and reactivation from dormancy in Mycobacterium smegmatis. Poster presentation at the Wits Health Sciences Research Day & Postgraduate Expo 2012. Wits Medical School, Johannesburg, South Africa, 19th September 2012.
  • Moolla N, Gordhan B. Construction and Phenotypic Characterization of Mycobacterium smegmatis Mutants Deficient in the Nth DNA Glycosylase. Poster presentation at the Wits Health Sciences Research Day & Postgraduate Expo 2012. Wits Medical School, Johannesburg, South Africa, 19th September 2012.
  • Moolla N, Gordhan B. Construction and Phenotypic Characterization of Mycobacterium smegmatis Mutants Deficient in the Nth DNA Glycosylase. Poster presentation at the SASBMB/FASBMB Congress 2012 - The South African Society of Biochemistry and Molecular Biology. Champagne Sports Resort, Drakensberg, KwaZulu-Natal, 29 January – 1 February 2012.
  • Goosens V, Mizrahi V, Gordhan B. The role of DNA glycosylases in mutagenesis and adaptation to stress in mycobacteria. Poster presentation at the Keystone Symposia |Drug resistance and persistence in tuberculosis. Kampala, Uganda. 13th – 18th May 2012.
  • Chengalroyen M, Kana B. The role of resuscitation promoting factors in the reactivation of Mycobacterium tuberculosis in sputum. Poster presentation at the Wits Health Sciences Research Day & Postgraduate Expo 2012. Wits Medical School, Johannesburg, South Africa, 19th September 2012.
  • Chengalroyen M, Kana B. A tool to improve the diagnosis of Mycobacterium tuberculosis. Poster presentation at the Spring Science Showcase. Delta Environmental Centre, Johannesburg, South Africa, 9th September 2012.
  • Chengalroyen M, Kana B. The role of resuscitation promoting factors in the reactivation of Mycobacterium tuberculosis in sputum. Poster presentation at the SASBMB/FASBMB Congress 2012 - The South African Society of Biochemistry and Molecular Biology. Champagne Sports Resort, Drakensberg, KwaZulu-Natal, 29 January – 1 February 2012.
  • Moller M. A CD14 promoter polymorphism is implicated in tuberculosis susceptibility in a South African population. Poster presented at the 62nd Annual Meeting of the American Society of Human Genetics, San Francisco, USA, 6 – 10 November 2012.
  • Daya M. A panel of ancestry informative markers for the South African Coloured population. Poster presented at the 62nd Annual Meeting of the American Society of Human Genetics, San Francisco, USA, 6-10 November 2012.
  • Salie M. HLA class-I supertypes are associated with specific M. tuberculosis strain infections. Poster presented at the 62nd Annual Meeting of the American Society of Human Genetics, San Francisco, USA, 6-10 November 2012.
  • De Vos M. Increasing levels of rifampicin resistance in Mycobacterium tuberculosis results in minor changes in the genomes of in vitro rifampicin resistant mutants. Poster presented at Keystone Symposium: E1, Drug Resistance and Persistence in Tuberculosis, Kampala, Uganda, May 2012.
  • Black PA. Regulatory response to Rifampicin in multi-drug resistant Mycobacterium tuberculosis strains. Poster presented at the Keystone Symposia on Drug Resistance and Persistence in Tuberculosis, May 2012.
  • Salie M. Poster presented at the EMBO|EMBL Symposium: New Perspectives on Immunity to Infection, Heidelberg, Germany, 19-22 May 2012.
  • Louw GE. Mycobacterium tuberculosis sputum cultures show polyphenotypic rifampicin resistance. Poster presented at Keystone Symposium, Drug Resistance and Persistence in Tuberculosis, Kampala Uganda, May 2012.
  • Le Roux. Novel SNP identification and association with bovine TB in African buffalo. Poster presented at the International Society of Animal Genetics (ISAG) 2012 conference, Cairns, Australia, 15-20 July 2012.
  • Willemse D. Regulation of efflux in rifampicin resistant mutants of Mycobacterium tuberculosis. Poster presented at the EMBO Tuberculosis 2012: Biology, pathogenesis, intervention strategies Conference, Institut Pasteur, Paris, France, 11-15 September 2012.
  • McGrath M. Nucleoside analogs and their possible role in the emergence of TB drug resistance.  Poster presented at the EMBO Tuberculosis: Biology, Pathogenesis, Intervention strategies Conference, Paris, France, 11-15 September 2012.
  • Viljoen A. Genetic study of the nitrogen assimilatory pathways of Mycobacterium bovis BCG. Poster presented at the EMBO Tuberculosis: Biology, Pathogenesis, Intervention strategies Conference, Paris, France, 11-15 September 2012.
  • Sao Emani C. The role of ergothioneine in the physiology of Mycobacterium smegmatis. Poster presented at the EMBO Tuberculosis: Biology, Pathogenesis, Intervention strategies Conference, Paris, France, 11-15 September 2012.
  • Fortuin S. A phosphoproteomic approach to characterise mechanisms of virulence in clinical M. tuberculosis Beijing strains. Poster presented at the Keystone Symposia (Proteomics, Interactomes), Stockholm, Sweden 2012. 
  • Fortuin S. The phosphoproteomes of a hypo- and hyper-virulent clinical M. tuberculosis Beijing strains. Poster presented at the MRC Early Career Scientist Conference, 25 October 2012.
  • Fang Z. Mycosin-3 of Mycobacterium tuberculosis, functional and structural studies.  Poster presented at the Structural Biology in the Bio Economy Conference, Cape Town, South Africa, 2-4 December 2012.
  • Parsons SDC. Development of a diagnostic gene expression assay for tuberculosis in African buffaloes (Syncerus caffer). Poster presented at the 8th Conference of the Federation of African Immunological Societies, Durban, December 2012.
  • Parsons SDC. A novel “dassie bacillus” variant isolated from meerkats. Poster presented at the International Wildlife TB Conference, Skukuza, KNP, September 2012.
  • Dippenaar A. Evolution of the members of the group 2 Latin American-Mediterranean (LAM) genotype of M. Tuberculosis. Poster presented at EMBO course:  Computational Biology: from genomes to cells and systems, 14-20 October 2012.
  • Ngwane A. Identification of a novel anti- M. tuberculosis compound (F1082) for TB drug development. Poster presented at Keystone Symposium, Drug Resistance and Persistence in Tuberculosis, Kampala Uganda, May 2012.
  • Ngwane A. Evaluation of Vav1Contribution in B cell Activation and Immunosuppression.  Poster presented at Novartis Next Generation of Scientist Meeting, 23 August 2012.
  • Loxton A. The frequency of CD103 as a marker of regulatory CD4+ T-cells and suppressor CD8+ T-cells is not affected by ARVs, but has a negative correlation with absolute CD4 cell numbers. Poster presented at the XIX International AIDS Conference, Washington DC, USA, 22-27 July 2012.
  • Loxton A. Regulatory T-cells and high levels of FOXP3 mRNA lead to decreased immune responses during HIV-TB co-infection .Poster presented at European Respiratory Society (ERS) 2012 Conference, Vienna, Austria, 1-5 September 2012.

Other Relevant Outputs (including honours and awards to staff)

  • SARCHi Research Chairs: The NRF has provisionally allocated 3 new SARCHi’s to the CBTBR in 2012, evidence of the strength of the CBTBR and the NRF’s confidence in the entity
  • Dr Bavesh Kana was selected as an Early Career Scientist of the Howard Hughes Medical Institute after a fiercely competitive process which involved almost 800 applicants worldwide. Dr. Kana is one of only 26 scientists from around the world to receive this prestigious award and represents one of only two awards made in Africa. The award comes with a $ 715 000 research grant, over the period of five years, Further details for this award can be found at http://www.hhmi.org/research/iecs/
  • Dr. Bavesh Kana was appointed as one of the top 200 Young South Africans by the Mail and Guardian newspaper. The Mail and Gaurdian 200 Young South African list comprises those individuals who are expected to make a significant impact in South Africa and play a key leadership role in the country. More details on this can be found at http://ysa2012.mg.co.za/
  • Dr Bhavna Gordhan was honored for her research achievements and leveraging significant research funding at the 2012 Annual Faculty of Health Sciences Research Awards.
  • Dr Bhavna Gordhan was awarded the Keystone Symposia Global Health Travel Award to attend the Keystone Symposium on Drug resistance and persistence in tuberculosis. Kampala, Uganda. 13th – 18th May 2012.
  • Dr Bavesh Kana was selected as an Early Career Scientist of the Howard Hughes Medical Institute after a fiercely competitive process which involved almost 800 applicants worldwide. Dr. Kana is one of only 26 scientists from around the world to receive this prestigious award and represents one of only two awards made in Africa. The award comes with a $ 715 000 research grant, over the period of five years, Further details for this award can be found at http://www.hhmi.org/research/iecs/
  • Prof. Mizrahi was selected as a Senior International Research Scholar of the HHMI and awarded five-year a $500,000 research grant. This highly prestigious SIRS award was given to 13 basic science researchers from countries outside the USA. This is Prof. Mizrahi’s third award from the HHMI. Details of this award can be found at http://www.hhmi.org/news/SIRS20120926.html. Dr. Williams was awarded a Columbia University-Southern African Fogarty AITRP Traineeship and a PHRI-AURUM-Global Infectious Diseases Research Fogarty Traineeship, July-Dec 2012
 

Research


© CBTBR 2006 | Last updated: 17 August, 2015